Five key insights into 2020’s drug royalty transactions

Providing additional opportunities for the monetisation of life sciences IP, the drug royalty market continued to develop in 2020, producing a slew of new deals with creative and flexible structures

Enter your details below to log into your account.

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Twitter

23 Jan 2021

@IAM_magazine The IAM Saturday Opinion: the US can reset IP engagement with China without giving up ground on key concerns about… https://t.co/YrTrDKRB7J Read more

22 Jan 2021

@IAM_magazine A new report points to a plunge in market share for Qualcomm in China underlining the importance of chip giant's li… https://t.co/FM5qia3CMX Read more

22 Jan 2021

@IAM_magazine The top patent prosecution firms in the US for 2020 https://t.co/D4dl0BkZsY @Oblon_IP @FishRichardson… https://t.co/Nef5rwMkI6 Read more

22 Jan 2021

@IAM_magazine Chinese lidar company reveals financial impact of its 10-year licensing agreement with Velodyne… https://t.co/8uPPGy96lR Read more